Lupin receives USFDA tentative approval for Dolutegravir and Rilpivirine Tablets
Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a generic equivalent of Juluca Tablets, 50 mg/25 mg of ViiV Healthcare Company.
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of USD 666 million in the U.S. (IQVIA MAT September 2022).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Buzzing :
Greece in crisisTravel & Budget & EuropeSaaS $ Email MarketingHarnautBlacklisting Policy 2Question Paper Leak 2A big moment for small armsAI in Financial Markets: How Technology is Changing Investing'India's size and diversity make it a powerful innovation engine'Datanomics: Housing, gold loans drive household debt to a decade highSamrat ChoudharyEl Nino
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jan 16 2023 | 1:47 PM IST